Status:

UNKNOWN

Modafinil in Treating Fatigue in Patients With Cancer

Lead Sponsor:

University of Virginia

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Cognitive/Functional Effects

Depression

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

RATIONALE: Modafinil may help relieve fatigue and improve quality of life in patients with cancer. PURPOSE: This clinical trial is studying how well modafinil works in treating fatigue in patients wi...

Detailed Description

OBJECTIVES: Primary * Determine the safety of modafinil in cancer patients. * Determine the efficacy of this drug, in terms of improving fatigue, in these patients. Secondary * Determine the effic...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of cancer
  • Brief Fatigue Inventory score ≥ 4
  • PATIENT CHARACTERISTICS:
  • Age
  • 18 and over
  • Performance status
  • ECOG 1-3
  • Life expectancy
  • At least 2 months
  • Hematopoietic
  • Not specified
  • Hepatic
  • Not specified
  • Renal
  • Not specified
  • Cardiovascular
  • No history of left ventricular hypertrophy
  • No history of ischemic ECG changes
  • No history of chest pain
  • No history of arrhythmia
  • No history of other clinically significant manifestations of mitral valve prolapse in association with CNS stimulant use
  • Other
  • Not pregnant or nursing
  • Negative pregnancy test
  • Thyroid stimulating hormone normal
  • No known hypersensitivity to modafinil
  • No history of psychotic disorder and/or active psychosis
  • No history of any chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation or compliance
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • Concurrent thalidomide allowed
  • Chemotherapy
  • Not specified
  • Endocrine therapy
  • Not specified
  • Radiotherapy
  • Not specified
  • Surgery
  • Not specified
  • Other
  • Concurrent narcotics, phenothiazines, or benzodiazepines allowed
  • No other concurrent investigational therapy

Exclusion

    Key Trial Info

    Start Date :

    February 1 2004

    Trial Type :

    INTERVENTIONAL

    End Date :

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT00112515

    Start Date

    February 1 2004

    Last Update

    August 20 2009

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Virginia Cancer Center

    Charlottesville, Virginia, United States, 22908